CD33 and acute myeloid leukemia: Furthermore, the post-remission therapy in the ALFA-0701 study for middle aged and older patients (age 50–70 years) used with two cycles of a combination with daunorubicin (60 mg/m2, day 1 first cycle and days 1–2 second cycle) and cytarabine (1 g/m2, bid, days 1–4) is also included for CD33 positive AML in the NCCN guidelines with GO (3 mg/m2, day 1) and is discussed further in the GO paragraph of the article [21, 25, 26].